Michael D George1, Joshua F Baker, Charles E Leonard, Samir Mehta, Todd A Miano, Sean Hennessy. 1. Division of Rheumatology (M.D.G. and J.F.B.), Department of Biostatistics, Epidemiology, and Informatics (M.D.G., J.F.B., C.E.L., T.A.M., and S.H.), and the Department of Orthopedic Surgery (S.M.), University of Pennsylvania, Philadelphia, Pennsylvania.
Abstract
BACKGROUND: Cyclooxygenase-2 (COX-2) has been found to be important for fracture-healing in animal models, raising concerns about use of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors after fractures. We evaluated associations of NSAIDs, COX-2 inhibitors, and opioids with nonunion after long-bone fracture. METHODS: Using private health insurance claims data from Optum's de-identified Clinformatics Data Mart database from January 1, 2000, to September 30, 2015, we identified adults with a single long-bone fracture or commonly paired long-bone fractures who had 1 year of available follow-up data. Using multivariable logistic regression models, we examined associations between NSAID, COX-2-inhibitor, or opioid prescription fills after the fracture and the risk of nonunion within 1 year, defined as a nonunion diagnosis with a procedure to treat the nonunion. RESULTS: A nonunion diagnosis with a procedure to treat the nonunion was identified after 2,996 (0.9%) of the 339,864 fracture episodes, with rates varying by fracture site. The risk of that outcome was greater in patients who had filled COX-2-inhibitor prescriptions (adjusted odds ratio = 1.84 [95% confidence interval = 1.38 to 2.46]) or opioid prescriptions (1.69 [1.53 to 1.86]), but not in patients who had filled nonselective-NSAID prescriptions (1.07 [0.93 to 1.23]) after the fracture. Results were similar when the outcome definition was changed to just a nonunion diagnosis. CONCLUSIONS: COX-2 inhibitors, but not nonselective NSAIDs, were associated with a greater risk of nonunion after fracture. Opioids were also associated with nonunion risk, although patients filling prescriptions for opioids may have had more severe fractures. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
BACKGROUND: Cyclooxygenase-2 (COX-2) has been found to be important for fracture-healing in animal models, raising concerns about use of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors after fractures. We evaluated associations of NSAIDs, COX-2 inhibitors, and opioids with nonunion after long-bone fracture. METHODS: Using private health insurance claims data from Optum's de-identified Clinformatics Data Mart database from January 1, 2000, to September 30, 2015, we identified adults with a single long-bone fracture or commonly paired long-bone fractures who had 1 year of available follow-up data. Using multivariable logistic regression models, we examined associations between NSAID, COX-2-inhibitor, or opioid prescription fills after the fracture and the risk of nonunion within 1 year, defined as a nonunion diagnosis with a procedure to treat the nonunion. RESULTS: A nonunion diagnosis with a procedure to treat the nonunion was identified after 2,996 (0.9%) of the 339,864 fracture episodes, with rates varying by fracture site. The risk of that outcome was greater in patients who had filled COX-2-inhibitor prescriptions (adjusted odds ratio = 1.84 [95% confidence interval = 1.38 to 2.46]) or opioid prescriptions (1.69 [1.53 to 1.86]), but not in patients who had filled nonselective-NSAID prescriptions (1.07 [0.93 to 1.23]) after the fracture. Results were similar when the outcome definition was changed to just a nonunion diagnosis. CONCLUSIONS: COX-2 inhibitors, but not nonselective NSAIDs, were associated with a greater risk of nonunion after fracture. Opioids were also associated with nonunion risk, although patients filling prescriptions for opioids may have had more severe fractures. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
Authors: Denise M Boudreau; Onchee Yu; Leslie Spangler; Thy P Do; Monica Fujii; Susan M Ott; Cathy W Critchlow; Delia Scholes Journal: Bone Date: 2012-11-19 Impact factor: 4.398
Authors: Robert Zura; Ze Xiong; Thomas Einhorn; J Tracy Watson; Robert F Ostrum; Michael J Prayson; Gregory J Della Rocca; Samir Mehta; Todd McKinley; Zhe Wang; R Grant Steen Journal: JAMA Surg Date: 2016-11-16 Impact factor: 14.766
Authors: Emil H Schemitsch; Mohit Bhandari; Gordon Guyatt; David W Sanders; Marc Swiontkowski; Paul Tornetta; Stephen D Walter; Rad Zdero; J C Goslings; David Teague; Kyle Jeray; Michael D McKee Journal: J Bone Joint Surg Am Date: 2012-10-03 Impact factor: 5.284
Authors: Aaron Daluiski; Keri E Ramsey; Yuexian Shi; Mathias P Bostrom; Bryan J Nestor; George Martin; Robert Hotchkiss; Dietrich A Stephan Journal: Orthopedics Date: 2006-03 Impact factor: 1.390
Authors: Bridget Sinnott; Cara Ray; Frances Weaver; Beverly Gonzalez; Elizabeth Chu; Sarah Premji; Mattie Raiford; Rachel Elam; Scott Miskevics; Stephen Parada; Laura Carbone Journal: JBMR Plus Date: 2022-01-05